Related Experiment Video
Updated: Jul 9, 2026

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
Published on: February 14, 2014
Trajectories of brain loss in aging and the development of cognitive impairment
N E Carlson1, M M Moore, A Dame
1Division of Biostatistics, Department of Public Health and Preventive Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd., Mail Code CB669 Portland, OR 97239, USA carlsoni@ohsu.edu
Background:
The use of volumetric MRI as a biomarker for assessing transitions to dementia presumes that more rapid brain loss marks the clinical transition from benign aging to mild cognitive impairment (MCI). The trajectory of this volume loss relative to the timing of the clinical transition to dementia has not been established.
Methods:
The authors annually evaluated 79 healthy elderly subjects for up to 15 consecutive years with standardized clinical examinations and volumetric brain MRI assessments of ventricular volume. During the study period, 37 subjects developed MCI. A mixed effects model with a change point modeled the pattern of brain volume loss in healthy aging compared with subjects diagnosed with MCI.
Results:
The brain loss trajectory of subjects developing MCI during follow-up differed from healthy aging in a two-phase process. First, the annual rate of expansion of ventricular volume decreased with age; however, the annual rates of expansion were greater in those who developed cognitive impairment during follow-up compared with those who did not. Further, subjects who developed MCI had an acceleration of ventricular volume expansion approximately 2.3 years prior to clinical diagnosis of MCI.
Conclusions:
Ventricular expansion is faster in those developing mild cognitive impairment years prior to clinical symptoms, and eventually a more rapid expansion occurs approximately 24 months prior to the emergence of clinical symptoms. These differential rates of preclinical atrophy suggest that there are specific windows for optimal timing of introduction of dementia prevention therapies in the future.
Insights
Brain volume loss accelerates years before mild cognitive impairment (MCI) diagnosis. This accelerated ventricular expansion, particularly 24 months prior to symptoms, offers potential windows for future dementia prevention therapies.
Area of Science:
- Neuroimaging
- Gerontology
- Neurology
Background:
- Volumetric MRI is a presumed biomarker for dementia transitions.
- Rapid brain volume loss is thought to mark the shift from normal aging to mild cognitive impairment (MCI).
- The precise trajectory of volume loss relative to clinical transition timing remains unestablished.
Purpose of the Study:
- To establish the trajectory of brain volume loss in relation to the clinical transition to dementia.
- To compare brain volume loss patterns in healthy aging versus those who develop MCI.
Main Methods:
- Annual clinical and volumetric brain MRI assessments of ventricular volume in 79 healthy elderly subjects over 15 years.
- 37 subjects developed MCI during the study.
- A mixed-effects model with a change point analyzed brain volume loss patterns.
Main Results:
- Brain loss trajectories differed between healthy aging and subjects who developed MCI.
- Annual ventricular expansion rates were higher in those who later developed MCI.
- Ventricular expansion accelerated approximately 2.3 years before MCI clinical diagnosis.
Conclusions:
- Ventricular expansion is notably faster in individuals who develop MCI, preceding clinical symptoms by years.
- A significant acceleration in ventricular expansion occurs around 24 months before symptom onset.
- These preclinical atrophy rates indicate potential windows for future dementia prevention interventions.
Related Concept Videos
Alzheimer Disease l: Introduction
Cognitive Development During Adulthood
Dementia l: Introduction
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia
The progression of dementia is generally gradual.
